Health Care [ 3/12 ] | Biotechnology [ 25/73 ]
NASDAQ | Common Stock
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer.
The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus.
It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma.
Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies.
The company was incorporated in 1997 and is headquartered in Pasadena, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 5, 25 | -0.08 Increased by +88.73% | -0.69 Increased by +88.41% |
| Aug 6, 25 | -0.41 Increased by +61.68% | -0.72 Increased by +43.06% |
| May 7, 25 | -0.66 Increased by +40.54% | -0.58 Decreased by -13.60% |
| Feb 25, 25 | -0.62 Decreased by -100.00% | -0.79 Increased by +21.14% |
| Nov 5, 24 | -0.71 Decreased by -77.50% | -0.98 Increased by +27.55% |
| Aug 5, 24 | -1.07 Decreased by -189.19% | -0.88 Decreased by -21.59% |
| May 9, 24 | -1.11 Decreased by -8.82% | -0.79 Decreased by -40.51% |
| Feb 27, 24 | -0.31 Decreased by -55.00% | -0.09 Decreased by -244.44% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 21.00 M Increased by +18.00% | -6.03 M Increased by +86.98% | Decreased by -28.70% Increased by +88.97% |
| Jun 30, 25 | 43.61 M Increased by +157.12% | -30.82 M Increased by +53.27% | Decreased by -70.69% Increased by +81.83% |
| Mar 31, 25 | 32.73 M Increased by +104.61% | -48.42 M Increased by +34.07% | Decreased by -147.92% Increased by +67.78% |
| Dec 31, 24 | 70.02 M Increased by +37.38% | -53.48 M Decreased by -104.53% | Decreased by -76.38% Decreased by -48.88% |
| Sep 30, 24 | 17.80 M Decreased by -69.92% | -46.29 M Decreased by -90.73% | Decreased by -260.10% Decreased by -534.09% |
| Jun 30, 24 | 16.96 M Decreased by -62.74% | -65.96 M Decreased by -200.46% | Decreased by -388.93% Decreased by -706.48% |
| Mar 31, 24 | 16.00 M Decreased by -15.64% | -73.44 M Decreased by -20.86% | Decreased by -459.09% Decreased by -43.26% |
| Dec 31, 23 | 50.97 M Increased by +135.84% | -26.15 M Decreased by -117.13% | Decreased by -51.30% Increased by +7.93% |